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Abstract The methylation status of the O6-methylgua-
nine-DNA methyltransferase (MGMT) gene is an important
predictive biomarker for benefit from alkylating agent
therapy in glioblastoma. Recent studies in anaplastic gli-
oma suggest a prognostic value for MGMT methylation.
Investigation of pathogenetic and epigenetic features of
this intriguingly distinct behavior requires accurate MGMT
classification to assess high throughput molecular data-
bases. Promoter methylation-mediated gene silencing is
strongly dependent on the location of the methylated CpGs,
complicating classification. Using the HumanMethyla-
tion450 (HM-450K) BeadChip interrogating 176 CpGs
annotated for the MGMT gene, with 14 located in the
promoter, two distinct regions in the CpG island of the
promoter were identified with high importance for gene
silencing and outcome prediction. A logistic regression
model (MGMT-STP27) comprising probes cg1243587 and
cg12981137 provided good classification properties and
prognostic value (kappa = 0.85; log-rank p \ 0.001) using
a training-set of 63 glioblastomas from homogenously
treated patients, for whom MGMT methylation was previ-
ously shown to be predictive for outcome based on
classification by methylation-specific PCR. MGMT-STP27
was successfully validated in an independent cohort of
chemo-radiotherapy-treated glioblastoma patients (n = 50;
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kappa = 0.88; outcome, log-rank p \ 0.001). Lower
prevalence of MGMT methylation among CpG island
methylator phenotype (CIMP) positive tumors was found
in glioblastomas from The Cancer Genome Atlas than in
low grade and anaplastic glioma cohorts, while in CIMP-
negative gliomas MGMT was classified as methylated in
approximately 50 % regardless of tumor grade. The pro-
posed MGMT-STP27 prediction model allows mining of
datasets derived on the HM-450K or HM-27K BeadChip to
explore effects of distinct epigenetic context of MGMT
methylation suspected to modulate treatment resistance in
different tumor types.
Keywords MGMT  DNA methylation  MSP 
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Introduction
High throughput platforms for genome wide DNA meth-
ylation analysis have allowed establishing the methylome
of large series of patient samples. Pattern analysis of
respective datasets has identified CpG island methylator
phenotypes (CIMP) for several tumor types such as colon
cancer [19, 21, 42] and more recently also glioma
(G-CIMP) [29, 43, 45]. However, classification of sam-
ples as being silenced by aberrant methylation for a given
gene is not obvious, since the relationship between CpG-
methylation at individual sites, the extent of the overall
CpG island methylation, and their effect on gene silencing
is strongly dependent on the location within the gene [46].
Promoter methylation of the repair gene O6-methylgua-
nine-DNA methyltransferase (MGMT) is a predictive
factor for benefit from alkylating agent therapy in glio-
blastoma patients [3, 16, 33]. The predictive value of the
MGMT status is supported by recent findings in two
clinical trials, comparing radiotherapy versus temozolo-
mide (TMZ) treatment. In these trials for elderly patients,
retrospective analysis of the MGMT methylation status
was associated with prediction of good outcome in the
TMZ-, but not the RT-arm [24, 52]. Furthermore, the
MGMT status has been prospectively validated in a phase
III trial as biomarker for favorable outcome in glioblas-
toma patients treated with temozolomide [12]. Repair by
MGMT reverses alkylation at the O6-position of guanine,
one of the most toxic lesions induced by alkylating agents
such as temozolomide (TMZ), thereby blunting the
treatment effect [18, 30]. Hence, the MGMT methylation
status has become a biomarker used for patient stratifi-
cation or patient selection in clinical trials for
glioblastoma patients [12, 39, 50]. Surprisingly, recent
studies in anaplastic glioma (WHO grade III) suggest a
prognostic value [44, 51]. In order to investigate patho-
genetic and epigenetic features associated with this
intriguingly distinct behavior of anaplastic glioma com-
pared to glioblastoma, it is of high interest analyzing large
datasets of glioma for which DNA methylome data have
been reported, and classifying them by their MGMT gene
promoter methylation status for integration into multi-
dimensional molecular and clinical data analysis. Several
glioma datasets comprising methylome data obtained
on the Infinium HumanMethylation27 (HM-27K) or
HM-450K BeadChip that interrogate at single-nucleotide
resolution over 27,000 or 485,000 methylation sites
per sample, respectively, have become publicly available
[7, 29, 43, 45]. The most comprehensive glioblastoma
dataset with over 200 samples is from The Cancer Gen-
ome Atlas [29, 40], widely used for hypothesis generation
and validation in brain tumor research [17, 48, 53];
however, the MGMT methylation status has not yet been
annotated.
The objective of this study was to propose a model
determining the probability of MGMT promoter methyla-
tion allowing classification into methylated and
unmethylated samples based on CpG methylation data
obtained on the widely used HM-450K or HM-27K
BeadChip. The model can be applied to other datasets for
example to further investigation of the relationship of
MGMT methylation with CIMP and other molecular and
clinical parameters. The basic idea was to train the model
using methylation-specific PCR (MSP)-based classification
that we have shown to predict favorable outcome in a
homogenously and prospectively treated glioblastoma
patient population and for which we have obtained HM-
450K data [15, 16]. Standard treatment included the
alkylating agent temozomoide (TMZ) concomitant with
and adjuvant to radiotherapy [36, 38]. At the same time,
this study allowed investigation of the relationship between
location-specific CpG methylation, MGMT gene expression
and outcome, supporting the mechanistic hypothesis that
methylation-dependent gene silencing results in loss of
expression and subsequently benefit from alkylating agent
therapy in glioblastoma.
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Material and methods
Patient samples and external data sets
DNA methylation profiles were established for 63 glio-
blastoma tissues from 59 patients and five non-tumoral
brain tissues (epilepsy surgery). All glioblastoma patients
were treated within a phase II or a randomized phase III
trial [36, 38] and provided written informed consent for
molecular studies of their tumors. The protocols were
approved by the ethics committees at each participating
center and the respective competent authorities. For this
patient cohort (M-GBM) that served as training set,
detailed clinical information, treatment [37] and molecular
data was available, including gene expression data [26],
and the MGMT methylation status based on classic meth-
ylation-specific PCR (MSP) [15, 16].
Four external glioma DNA methylation datasets associated
with clinical information were used: the first, prospectively
collected glioblastoma samples of a cohort of 50 patients
(E-GBM) treated with combined chemo-radiotherapy with
TMZ (Stupp protocol) for which HM-27K and methylation-
specific pyrosequencing-based (MS-PSeq) MGMT methyla-
tion information was available [7] (see supplementary Figure
S1 for location of five interrogated CpGs). The second dataset
with HM-27K information consisted of 241 glioblastoma
samples (TCGA-GBM, survival information available for 239
samples) and was downloaded from The Cancer Genome
Atlas (TCGA) website (http://tcga-data.nci.nih.gov/tcga/tcga
Home2.jsp) [29, 40]. The third comprised HM-27K data from
67 anaplastic glioma (WHO grade III) (VB-Glioma-III) [45]
of a cohort of homogenously treated patients, including
MGMT methylation classification based on methylation-
specific multiplex ligation-dependent probe amplification
(MS-MLPA) (see Figure S1 for location of the 3 interrogated
CpGs, probes used are described [44]). The fourth dataset
comprised 71 low grade and anaplastic glioma samples (29
WHO grade II and 42 grade III) profiled on the HM-450K
(T-Glioma-II/III) [43].
DNA methylation analysis
DNA was isolated from frozen tissues whereof 1.0-lg DNA
was converted by bisulfite using the EZ DNA MethylationTM
Kit (# D5001 Zymo Research Corporation) according to the
manufacturer’s instructions. DNA methylation analysis was
performed on the HM-450K (Illumina) as recommended at the
Genomics platform at the University of Geneva. For each
interrogated CpG two site-specific probes are present, one
designed for the methylated and another for the unmethylated
locus to which the chemically converted DNA gets hybrid-
ized. Single-base extension of the hybridized probes
incorporates a labeled ddNTP, which allows subsequent
quantification of methylated and unmethylated alleles (http://
www.illumina.com/technology/infinium_methylation_assay.
ilmn).
Data analysis
The intensities of methylated and unmethylated signals
were normalized using the Illumina GenomeStudio pro-
gram. In the annotation file 176 CpG probes were
associated with the MGMT gene, whereof 25 are shared
with the HM-27K that was used in three of the four
external datasets. The DNA methylation information was
summarized by M-value as recommended by Du et al. [4]:
M-value ¼ log 2 max signal B; 0ð Þ þ 1
max signal A; 0ð Þ þ 1
 
:
The terms ‘signal A’ and ‘signal B’ correspond to the
intensities of the unmethylated and methylated probes.
Statistical methods
The relationship between the methylation status of the MGMT
promoter defined by MSP and the probes located in the MGMT
promoter region (CHR10: 131264700-131266300, genome
build 37) (Fig. 1; Fig. S1) present on the HK-450K was
evaluated by logistic regressions [25, 28]. A two-step proce-
dure was used to construct the model to calculate the
probability of MGMT promoter methylation for subsequent
binary classification. In the first step, all univariate models
were tested and only probes significantly associated with the
MSP classification were selected using the log-likelihood ratio
test (LRT) and Bonferroni correction for multiple testing. In a
second step, we determined the optimal model built by step-
wise logistic model building based on the corrected Akaike’s
criterion (AICc) [1, 20, 47] that limits overfitting. Two models
were constructed, one with all selected probes, and one using
only the probes common to both, the HM-27K and HM-450K
platforms. The model performance was assessed by internal-
validation based on a bootstrap procedure with optimism/bias
correction [13]. This procedure validates the process used to fit
the original model and it provides a bias value defined by the
difference between the index from the original dataset and the
average of indices from the resampling procedure (200 repe-
titions). The kappa index and the proportion of correct
classification were used to evaluate the concordance between
the observed and the predicted methylation status. The
M-value distributions of the probes selected by the model
were compared by pairwise quantile-quantile representation
(QQ-plot) for the five datasets and non-parametric Smirnov–
Kolmogorov test for equal distribution.
For the external datasets, the probability of MGMT
promoter methylation and subsequent classification were
determined using the model compatible with the HM-27K
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platform. The probability values were associated with
Wald-based confidence intervals (CI 95 %) to evaluate the
uncertainty of the model [9]. CIMP positive tumors were
identified using unsupervised clustering methods similar to
Noushmehr et al. and Turcan et al. [29, 43]. The relation-
ship between the predicted MGMT status and the presence
of CIMP was assessed by Chi-squared tests with p values
computed by Monte Carlo simulation, because cell counts
were expected to be inferior to five [31].
The Kaplan–Meier (KM) curves and log-rank tests were
estimated for each dataset and predictor [13, 41]. Univar-
iate and multivariate survival models were assessed using
the Cox proportional hazards regression model and the
LRT.
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Fig. 1 CpG methylation of the MGMT promoter region, MGMT
expression and patient survival in M-GBM. a The Spearman and
Pearson correlations between gene expression (probe 204880_at from
Affymetrix U133plus2) and M-value of the 18 CpG methylation
probes from the Infinium humanmethyltion 450K BeadChip (HM-
450K) of the M-GBM cohort are visualized on a scale representing
the physical location in the CpG island of the promoter region
encompassing the transcription start site (TSS) (genome build 37).
b The associations between overall survival (OS) and CpG methyl-
ation of distinct probes are displayed (p values, univariate Cox
regression model and log-likelihood ratio test; p values, minus-log10-
transformed). The p value for classification by MSP is indicated at its
physical location (primer set, red). c The associations between MGMT
promoter methylation classification based on MSP and the 18 selected
CpG methylation probes from the HM-450K are shown (logistic
regression and log-likelihood ratio test; p values, minus-log10-
transformed). The dotted gray lines in b and c correspond to the
threshold of 0.05. The graph at the bottom indicates the physical
location of the TSS (TSS1, according to Harris et al. [14]; TSS2
according to gene build 19); the location of the CpG island/individual
CpGs green; the differentially methylated regions 1 and 2, DMR1 and
2, as defined by Malley et al. [23] blue; the primers for MSP [6] red;
the region for MS-clone sequencing in glioblastoma, MS-CSeq [34];
the CpGs interrogated by methylation specific multiplex ligation-
dependent probe amplification, MS-MPLA purple [44], and methyl-
ation-specific pyrosequencing, MS-PSeq pink [7]. The names of the
CpG probes interrogated on HM-450K are given on the right. Probes
present on both platforms (HM-450K and HM-27K) are indicated by
triangles, probes only present on the HM-450K are represented by
squares. See supplementary Figure S1 for exact locations of CpGs
interrogated by the different assays. The symbols are explained on the
right hand side. We note that the CpG methylation probes (8, 9, 10
and 16) most correlated with expression also correspond to the probes
highly associated with survival, and most correlated with MSP-based
MGMT methylation prediction
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Analyses and graphical representations were performed
using R-2.14.2 and the R packages design and survival
[32].
Results
Calibration model to predict the methylation status
of the MGMT promoter using the HM-450K platform
The prediction model is based on a glioblastoma patient
cohort treated with standard chemo-radiotherapy within
two prospective clinical trials. The MGMT promoter
methylation status of this cohort was available from classic
MSP discriminating methylated and unmethylated samples.
Most importantly, the results of this MSP-test have been
shown to be of predictive value for benefit from the addi-
tion of temozolomide chemotherapy [15, 16, 26, 37]. The
results of the MSP assay were considered as reference for
model construction. A total of 63 glioblastoma samples
(M-GBM) and five non-tumoral brain tissues were analyzed
on the HM-450K Beadarray platform. The five non-tumoral
brain tissues were classified as MGMT unmethylated based
on MSP. The clinical and molecular information of patient
samples is summarized in Table S1. Of the 176 CpG probes
on the HM-450K annotated as mapping to the MGMT gene,
14 are in the CpG island located in the MGMT promoter
region encompassing the transcription start site (TSS)
(Fig. 1). This CpG island has been shown to be determinant
for regulation of expression [8, 23, 27, 35]. The remaining
CpGs are mostly found in the MGMT gene body (Supple-
mentary Figure S2). The detection call rate for these 14
CpG island-associated probes was equal to 1.00, indicating
reliable detection.
Association of probes with MSP, MGMT expression
and outcome
Eleven probes located in the TSS-encompassing CpG
island of the MGMT promoter were significantly associated
with the previously MSP-defined MGMT methylation sta-
tus (Fig. 1). We observed two prediction peaks. The
strongest association was reached by the probes
cg12434587 and cg12981137, respectively (No. 10 and 16
in Fig. 1). Of note, the CpG tested by the probe
cg12981137 (CHR 10: 131265575, genome build 37) is
also interrogated by the reverse primer of the MSP assay
(Supplementary Fig. S1) [6]. Strikingly, the highest nega-
tive correlation between methylation and gene expression
(estimated by Affymetrix U133plus2, [26]) was observed
for the same two probes (Spearman correlation coefficients
-0.543 and -0.571, respectively). The negative correla-
tion is consistent with promoter methylation mediated
down-regulation of MGMT expression. Similarly, these
two probes were the most negatively correlated with
MGMT gene expression in the E-GBM and the TCGA-
GBM dataset for which expression data were available
(Supplementary Fig. S3). The association of MGMT
expression and DNA methylation at individual CpGs is
visualized in a scatter plot for the M-GBM data set
including non-tumoral brain tissues in the Supplementary
Figure S4. Remarkably, the probes in vicinity to the TSS
(probes 12–14 in Fig. 1) were at best weakly associated
with the MSP results (Fig. 1). The strongest association
with overall survival (OS) peaked at the same two probes,
cg12434587 and cg12981137, with p values of\10-5 and
\10-4, while again no association was found at CpGs in
the vicinity of the TSS, and the 50 and 30 edges of the CpG
island (Fig. 1). The p values for OS prediction of these two
probes were similar to the one for the MSP-based meth-
ylation classification (p \ 10-5). The association of OS
with methylation at individual CpGs is shown for all
datasets in Figure S3. Taken together, the CpG methylation
probes (8, 9, 10 and 16) most correlated with expression
also correspond to the probes highly associated with
survival, and most correlated with MSP-based MGMT
methylation prediction.
In order to test if other methylated CpGs are relevant for
MGMT silencing, we investigated the remaining CpGs,
mainly located in the gene body. No negative correlation
was observed between methylation and expression and no
association with outcome (Supplementary Figure S2).
Stepwise model building
We aimed at building an optimal methylation predictor
using multiple probes. In the first step, the 11 probes sig-
nificantly associated with MSP-defined methylation were
selected. The prediction performances with individual
probes were very high. Expectedly, the highest sensitivity
and specificity values were obtained for the probes
cg12981137 and cg12434587 (0.906 and 0.944; 0.875 and
0.944) (Fig. 1). Nonetheless, stepwise model building (see
‘‘Methods’’) indicated that MSP assay classification could
be predicted even better using two or more probes.
The best model based on probes shared with the HM-
27K platform (see Fig. 1) comprised the two probes
cg12434587 and cg12981137 (MGMT-STP27 model). The
adjustment of the model was of high quality (supplemen-
tary Table S2). The sensitivity and specificity were equal to
0.969 and 0.889, respectively (Fig. 2). The proportion of
correct classification (0.926), the kappa index (0.853), and
the AUC (0.974) confirm the good performance of the
model. The hazard risks (HR) based on MSP and the
MGMT-STP27 model were similar (log-rank test for both,
p \ 0.001; MSP, HR = 0.229, 95 % confidence interval
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(CI 95 %) = [0.115, 0.454]; MGMT-STP27, HR = 0.277,
CI 95 % = [0.145, 0.529]) (Fig. 2). The equation for this
model is given below:
logit yð Þ ¼ 4:3215 þ 0:5271  cg12434587
þ 0:9265  cg12981137 :
The methylation probability y can be computed using
the inverse logit function. For classification, we used a
probability cut-off of 0.358, which empirically maximized
the sum of sensitivity and specificity (supplementary Table
S2; annotation of M-GBM sample classification
supplementary Table S1). The classification by STP27
and MSP is visualized in Fig. 2a. Furthermore, the
classification by STP27 is projected onto the scatter plots
comparing expression and DNA methylation at individual
CpGs, reclassification from MSP-based prediction are
indicated (Supplemental Figure S4).
The second model, obtained using all 11 probes avail-
able on the HM-450K platform contained 4 probes: the two
probes also selected in MGMT-STP27 (cg12981137,
cg12434587) plus cg02022136 and cg23998405. The
improvement over MGMT-STP27 is only marginal (infe-
rior to 1 unit of the AICc, supplementary Table S2).
However, the latter model showed a high inflated variance
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Fig. 2 Performance of the stepwise logistic regression model
(MGMT-STP27) for prediction of methylation status of the MGMT
promoter. a Displays the estimated probability of methylation against
the logit-transformed response fitted for the M-GBM dataset. The
observed values are given by full black squares, indicating same or
different classification by STP27 or MSP. Fitted values and their
confidence intervals [CI] at 95 %, estimated by simulation, corre-
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lines indicate the threshold used to define methylated and unmethy-
lated samples. b The receiver operating characteristic (ROC) curve is
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factor (8.9, supplementary Table S2) that reflects a problem
of multi-colinearity. Consequently, this model was not
considered for further analyses.
The internal validation based on the bootstrap procedure
showed that the model MGMT-STP27 was relatively stable.
The unbiased diagnostic accuracy (proportion of correct
classification) was estimated to 91.24 %, against 92.65 %
initially computed on the original dataset. For the kappa index,
the difference between unbiased and original value was only
equal to 0.03 units (supplementary Table S3).
External validation of MGMT-STP27
We validated the use of the MGMT-STP27 model in an
external data-set of 50 glioblastoma (E-GBM) analyzed on
the HM-27K [7]. We dichotomized the MS-PSeq infor-
mation of the MGMT promoter available for 47 cases into
methylated and unmethylated. The cut-off was estimated at
7.28 % average methylation based on a fitted regression
model visualized in supplementary Figure S5 which is
similar to previous reports applying a cut-off of 8 % using
the same MS-PSeq kit [10, 33]. The correspondence
between the predicted status of MGMT promoter methyl-
ation using MGMT-STP27 and MS-PSeq information was
very high, as visualized in Fig. 3a with a proportion of
correct classification of 0.936, a kappa index of 0.875, and
sensitivity and specificity equal to 0.931 and 0.944,
respectively. Outcome prediction using MS-PSeq infor-
mation or MGMT-STP27 was as follows: p = 0.019,
HR = 0.454, CI 95 % [0.232; 0.891] for MS-PSeq, and
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Fig. 3 Validation of MGMT-STP27 in external datasets. The plots
a and d represent the estimated probability of methylation against
logit-transformed response fitted for the E-GBM, and VB-Glioma-III
datasets using STP27. Fitted values and their prediction intervals [PI]
at 95 %, estimated by simulation, correspond to the red line and gray
area, respectively. Dark green dotted lines indicate the threshold used
to define methylated and unmethylated samples according to STP27.
The observed values are visualized by full black squares, indicating
same or different classification by STP27 or MS-PSeq for E-GBM
and MS-MLPA test for VB-Glioma-III, respectively. The Kaplan–
Meier curves are based on classification by MS-PSeq for E-GBM (b),
the MS-MLPA test for VB-Glioma-III (e), and based on the
respective predicted methylation status using MGMT-STP27, in
(c, f). Results of log-rank tests are given below each survival
representation. M methylated, U unmethylated
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p \ 0.001, HR = 0.305, CI 95 % = [0.156; 0.596] for
MGMT-STP27 (Fig. 3).
Next, we tested the model in a dataset from a cohort of
anaplastic oligodendroglioma and anaplastic oligoastrocy-
toma (WHO grade III) (VB-Glioma-III, n = 67) generated
with the 27K-platform [45]. The methylation status of the
MGMT promoter was available from MS-MLPA for most
cases (n = 62). We observed a good concordance (Fig. 3d)
with a good classification rate of 0.839, a kappa index of
0.628, and sensitivity and specificity equal to 0.975 and
0.609, respectively. As reported by van den Bent et al. [45],
MGMT methylation as determined by MS-MLPA was
significantly associated with favorable outcome of the
patients with a p value of 0.031 (log-rank test)
(HR = 0.527, CI 95 % = [0.292, 0.952]). This is similar
to the prediction by our MGMT-STP27 model with a
p value of 0.029 (HR = 0.500, CI 95 % = [0.266, 0.941])
as visualized in Fig. 3.
Prediction of MGMT methylation status
in TCGA-GBM cohort and a glioma
grade II and III data set
The good performance of the MGMT-STP27 model in the
two external data-sets suggests that we can appropriately
predict the MGMT methylation status using common probes
between the HM-450K and HM-27K platforms. Prediction
of the MGMT methylation status in 241 glioblastoma avail-
able from TCGA (TCGA-GBM) with HM-27K data
revealed a methylation frequency of 50 % (120/241) (see
annotation of samples in supplementary Table S4 that also
includes more recent samples analyzed on the HM-450K
platform) similar to our M-GBM cohort. Patients from the
TCGA-GBM dataset (n = 239) with a MGMT methylated
glioblastoma had a more favorable outcome (p = 0.047, log-
rank test, Fig. 4). The HR for the predicted methylation
status was equal to 0.737 (CI 95 % = [0.545, 0.997]).
The prediction of the MGMT methylation status using
MGMT-STP27 in a cohort of grade II and III gliomas
(T-Glioma-II/III) with HM-450K data, determined a methyl-
ation frequency of 79 % (32/42) in grade III glioma and 86 %
(25/29) in grade II. The favorable outcome associated with
MGMT methylation was confirmed as visualized in Fig. 4.
Associations of MGMT methylation across tumor
grades of glioma
Next, we asked whether MGMT is part of the genes asso-
ciated with CIMP using the TCGA-GBM data set [29].
Glioblastoma with a methylated MGMT promoter were
significantly enriched among CIMP cases (15/20, 75 %
against 105/221, 48 %; p = 0.023, Table S5). However,
the two MGMT probes selected in our prediction model do
not cluster with the CIMP core genes as visualized in the
heatmap of supplementary Figure S6. Classification of the
glioblastoma into the three methylation clusters (CIMP?,
and 2 non-CIMP clusters) as published by Noushmehr et al.
[29] were available for 81 samples with HM-27K DNA
methylation (Fig. 5, Supplementary Fig. S6). The 10
CIMP? samples defined by the authors were all in the
CIMP cluster obtained by unsupervised clustering methods
in the present study. The distribution of samples with
methylated MGMT was not significantly different for the
two non-CIMP methylation clusters (p = 0.214, Monte
Carlo simulation) defined by Noushmehr et al. [29].
No association was found between the MGMT status and
any of the expression-based glioblastoma subtypes pro-
posed by Verhaak et al. [48] (p = 0.518, Monte Carlo
simulation) (Fig. 5; Table S5).
In contrast, in both the VB-Glioma-III and the T-Gli-
oma-II/III datasets basically all tumors clustering together
displaying CIMP were classified as MGMT methylated by
the MGMT-STP27 model (32/32 and 48/49), while the
CIMP-negative tumors exhibited a methylation frequency
of 54 % (19/35) and 50 % (11/22) that is similar to the
three glioblastoma datasets (Figs. 5, 6). Hence, the asso-
ciation of methylated MGMT with CIMP was much
stronger in low grade and anaplastic glioma than in the
TCGA-GBM. The difference is highly statistically signifi-
cant (Chi-squared test with p value estimated by Monte
Carlo simulation; 32/32 vs. 15/20, p \ 0.005 for VB-Gli-
oma-III and 48/49 vs. 15/20, p \ 0.005 for T-Glioma-II/
III). In the VB-Glioma-III dataset this association was
retained when using the CIMP classification published by
van den Bent et al. (MGMT methylated among CIMP?,
30/30; Fig. 5).
Comparisons of M-value distribution across datasets
and platforms
The pairwise comparisons of the M-value distribution for
the two probes cg12434587 and cg12981137 across data-
sets revealed that M-value were generally higher in the
grade II/III glioma (VB-Glioma-III, T-Glioma-II/III) as
compared to glioblastoma (M-GBM and TCGA-GBM)
(p \ 0.05 from Kolmogorov–Smirnov tests, supplementary
Figure S7). However, the comparisons between the glio-
blastoma datasets, analyzed on the HM-450K (M-GBM)
and the HM-27K (TCGA-GBM), respectively, showed
similar M-value distributions (p = 0.260 and p = 0.145,
supplementary Figure S7). Likewise, the M-value distri-
butions among the datasets of grade II and III gliomas
analyzed on the HM-27K (VB-Glioma-III) and the HM-
450K (T-Glioma-II/III), respectively, were similar
(p = 0.435 and p = 0.233, supplementary Figure S7).
Hence, indicating that differences observed between the
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studies were not due to a platform effect, but rather result
from biological differences. Consequently, this could affect
(bias) the prediction quality of the methylation status of
MGMT for grade II and III glioma by MGMT-STP27, and
may explain the higher number of positive calls by
MGMT-STP27 when compared to MS-MLPA (specificity
of only 0.609 when using MGMT-STP27 as predictor of
MS-MLPA methylation calls). However, outcome predic-
tion was equally good for both methylation call methods in
the VB-Glioma-III data (Fig. 3).
Discussion
The analysis of the MGMT gene in glioblastoma using
HM-450K methylation data has shown a strong CpG
location-dependent effect on patient outcome. To our
knowledge, this is the first report describing the spatial
relationship of CpG methylation in the MGMT promoter
and the gene body and outcome of patients treated with
alkylating agent therapy. Two regions of methylated CpGs
with strong association to patient survival were identified
(p \ 0.0001 after Bonferroni’s correction) that are sepa-
rated by a prediction minimum at the TSS. The two
identified regions were also associated with the strongest
negative correlation to MGMT gene expression, consistent
with CpG methylation-mediated gene silencing and con-
sequent sensitization to alkylating agent therapy due to lack
of MGMT-mediated repair in this homogenously treated
patient population. The two regions identified encompass
the differentially methylated regions 1 and 2 (DMR1 and 2,
Fig. 1) proposed by Malley et al. [23] to be most relevant
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Fig. 4 MGMT-STP27 based prediction in external datasets. The first
plots in (a) and (c) represent the estimated values (probability of
methylation fitted against response fitted in link space) for the GBM-
TCGA and T-Glioma-II/III datasets. Fitted values and their prediction
intervals [PI] at 95 %, estimated by simulation, correspond to the red
line and gray area, respectively. Dark green dotted lines indicate the
threshold used to define methylated and unmethylated samples. The
white squares correspond to the deduced methylation status. The
Kaplan–Meier curves are based on classification by prediction using
MGMT-STP27 for TCGA-GBM (b), T-Glioma II/III (d), or only
T-Glioma-III (e), Results of log-rank tests are given below each
survival representation. M methylated, U unmethylated
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Fig. 5 Distribution of MGMT methylation and CIMP status. The
dendrogram for each dataset is provided. The five datasets were
centered and normalized by probes followed by unsupervised
hierarchical classifications of the 1,000 most variable probes (auto-
somes only) using Ward’s algorithm and Euclidean distance to
establish CIMP classification (green rectangle for non-CIMP and red
for CIMP). The methylation status of the MGMT promoter predicted
by MGMT-STP27, blue for unmethylated, and red for methylated, is
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established in the respective original publication (if available),
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TCGA-GBM; u unvalidated; v validated), classification into methyl-
ation clusters according to Noushmehr et al. [29] (cluster annotation
Level 4 data, TCGA data portal), and gene expression based
glioblastoma classification using a modified model from Verhaak
et al. [48], tumor grade (for T-Glioma-II/III), and methylation status
of MGMT promoter based on MSP, MS-MLPA, and MS-PSeq,
unmethylated, light green; methylated, darkgreen. The color code for
the labels is displayed
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for gene silencing when methylated in glioblastoma cell
lines and xenografts. Shah et al. [35] defined three relevant
regions, of which R2 and R3 encompass DMR1 and 2, and
methylation of two of these three regions were associated
with favorable progression free survival in their population
of 44 glioblastoma patients treated with RT and concomi-
tant and adjuvant TMZ. Most importantly, the region
interrogated for diagnostic purposes using MSP [5, 16]
overlaps with the CpGs associated with best outcome
prediction identified here. In contrast, none of the 161
CpGs interrogated outside the CpG island, located mostly
in the gene body, showed an association with outcome, or a
negative correlation with MGMT expression (Supplemen-
tary Figure S2). However, we cannot exclude that other
CpGs may be more relevant as the once described here,
since the BeadChip array does not interrogate all CpGs of
the CpG island encompassing the MGMT promoter (Sup-
plementary Fig. S1).
The CpG methylation probes present on the HM-450K
and HM-27K BeadChip identified to be most relevant for
gene silencing and outcome allowed construction of a
model for prediction of the MGMT methylation status. The
use of logistic regression provides a simple model to cal-
culate the methylation probability for a new sample based
on two probes. Its ability to compute confidence and pre-
diction intervals [2, 20] may be of particular interest for
treatment decisions for patients whose tumors display
methylation probabilities close to the cut-off (Figs. 2, 3, 4).
This allows application of a ‘‘safety margin’’ as we do in
EORTC26082 (NCT01019434) that selects unmethylated
glioblastoma patients only (cut-off set at lower bound of
95 % CI using a quantitative MSP assay [49]), since it omits
TMZ, thereby limiting the risk to withhold TMZ in patients
who may potentially profit from it. The model’s good per-
formance is reflected in similar or improved prediction of OS
as compared to the MSP-based classification or MS-PSeq-
based prediction in the E-GBM validation set, in accordance
with high values for good classification, kappa value, and
sensitivity and specificity measures (Figs. 2, 3).
Our model can be used for both the HM-450K and the
HM-27K BeadChip. The platform effect was very weak. A
higher amplitude of the methylation signal was detected in
the low grade and anaplastic glioma samples that may
simply reflect the fact that in non-glioblastoma usually both
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MGMT copies are present, while in glioblastoma only one is
methylated and the other one is lost due to the characteristic
high frequency of deletions of chromosome 10 that reached
90 % in the M-GBM samples [22]. Consequently, the pres-
ence of two methylated MGMT copies will lead to an increase
of the ratio methylated to unmethylated alleles. For the model,
however, this may generate a bias in the estimation of MGMT
methylation probabilities based on the MGMT-STP27 model
for non-glioblastoma tumors. The estimation could be
improved by determining new optimal parameters in this
population. Nevertheless, despite these limitations classifi-
cation using the MGMT-STP27-based outcome prediction of
the VB-Glioma-III dataset was similar to the one reported by
the authors who used another method of MGMT testing
(Fig. 3). Prediction of the MGMT status in the TCGA-GBM
confirmed a favorable outcome for patients with MGMT
methylation, although the effect was weaker than in our
homogenously treated cohort (M-GBM) and the E-GBM
cohort in which all patients were treated with combined
chemo-radiotherapy comprising TMZ. This is not surprising,
since most patients in the TCGA cohort had not (yet) been
treated according to the current standard of care of combined
chemo-radiotherapy (collection before 2005), and many dif-
ferent types of therapy were reported for the patients in the
respective annotation file [29].
The annotation of the MGMT status in the TCGA-GBM
dataset according to MGMT-STP27 allowed determining
that MGMT is not a CIMP gene in glioblastoma although
CIMP tumors were more likely to be MGMT methylated.
Further, the prevalence of MGMT methylated glioblastoma
is not different in the two non-CIMP methylation clusters
defined by Noushmehr et al. [29], nor are they enriched in
any of the expression-based glioblastoma subtypes, sug-
gesting that MGMT methylation is not associated with a
particular pathogenetic mechanism involved in the devel-
opment of de novo glioblastoma.
This is in contrast to grade II and III glioma (VB-Gli-
oma-III and T-GliomaII/III) in which MGMT is methylated
in basically all CIMP tumors according to our classification
model. It has been proposed that MGMT methylation may
represent an epiphenomenon of CIMP in the context of
grade III glioma [45]. This association of CIMP with
MGMT methylation may provide the key to understand
why MGMT methylation is associated with a prognostic
and not a predictive value for benefit from alkylating agent
containing chemotherapy in anaplastic glioma as suggested
by two independent clinical trials [44, 51]. Most of the VB-
Glioma-III samples analyzed here in fact originate from
one of these two studies and were characterized for CIMP
[45]. Anaplastic gliomas with CIMP accumulate other
known favorable prognostic factors such as mutations of
the isocitrate dehydroxygenase (IDH) genes, 1p/19 co-
deletions, and also MGMT promoter methylation, in addition a
plethora of other methylated genes whose contribution to
response to therapy remains to be explored and exploited. It
has become clear that these CIMP-positive tumors represent a
pathogenetically different disease driven by epigenetic alter-
ations mediated in most cases by IDH1/2 mutations [11, 43].
Interestingly, non-CIMP anaplastic gliomas showed a MGMT
promoter methylation frequency similar to glioblastoma. It
remains to be seen if in this CIMP-negative patient subpop-
ulation the MGMT status is predictive for benefit from
alkylating agent therapy like in glioblastoma or has a prog-
nostic value. This question can be addressed in the ongoing
CATNON trial (EORTC 26053-22054; NCT00626990) for
anaplastic glioma comparing radiation therapy with or with-
out temozolomide. The same question applies to low-grade
glioma where radiation versus temozolomide treatment is
tested (EORTC 22033-26033, NCT00182819) and the role of
CIMP and MGMT methylation will need to be dissected. Since
the HM-450K BeadChip allows the use of paraffin-embedded
tumors, comprehensive DNA methylation analysis of samples
collected within these clinical trials has become feasible.
The proposed MGMT-STP27 MGMT classification
model will allow investigation of distinct epigenetic fea-
tures associated with MGMT silencing in the context of
CIMP-positive or CIMP-negative gliomas by multidimen-
sional analysis of respective molecular and clinical data.
Such alterations likely modulate response to therapy and
may be exploited for improvement of personalized therapy.
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